Lonza Group stock holds steady as focus turns to business context
Published on 07/13/2026 at 21:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lonza Group (ISIN CH0013841017) is a Swiss life sciences supplier whose business spans pharmaceutical development, manufacturing services and specialty ingredients.
Business profile
The company serves biopharma customers with integrated capabilities that support drug substance production and related services, making its revenue mix more structurally tied to pharmaceutical outsourcing than to consumer demand. That mix is the key interpretive point for investors: Lonza is less a single-product story than a capacity, execution and customer-partnership story.
Market context
Lonza Group shares trade on the SIX Swiss Exchange in Swiss francs, and the stock is best read through the lens of contract manufacturing demand, regulated operations and long-cycle customer programs.
Relative to broader healthcare names, that gives the company a different sensitivity profile, with order flow and plant utilization often mattering more than headline product cycles.
Representative product
Among Lonza's better-known offerings are its CDMO services, which support customers from development work through commercial manufacturing.
Stock snapshot
Lonza Group shares trade on the SIX Swiss Exchange in CHF. The company is listed in Switzerland under ISIN CH0013841017.
Lonza Group fact box
- Company: Lonza Group AG
- ISIN: CH0013841017
- Ticker: LONN
- Exchange: SIX Swiss Exchange
- Sector / Industry: Healthcare, life sciences tools and services
- Index membership: Swiss Market Index
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
